TORONTO, ONTARIO--(Marketwired - Oct. 3, 2016) - Hemostemix Inc. (the "Corporation") (TSX VENTURE:HEM)(OTCQB:HMTXF), a clinical-stage autologous cell-therapy company, announces that two new patents have been granted in 2016 in the United States and Canada.
The U.S. Patent and Trademark Office (USPTO) granted patent US 9,404,084 titled "Regulating Stem Cells". Itis the fourth Hemostemix patent issued in the United States. The patent covers a method for generating therapeutic cell products, including the company's lead product ACP-01 and cardiomyocyte -like precursor cells. These precursor cells - which is isolated from a simple blood collection - are generated from a core population of cells named "Synergetic Cell Population" (SCP). The Hemostemix technology enables proprietary cells, grown from a patient's blood, to be injected into that same patient's diseased tissue in order to restore its function.
In addition to its capacity to grow new blood vessels, SCP can, using proprietary cell-culturing techniques, give rise to other cell types, such as cardiomyocyte-like and neural-like precursor cells.
Growing SCP into neural -like precursor cells is the scope of patent CA 2,632, 836, recently issued in Canada and titled "Production from Blood of Cells of Neural Lineage".
"The newly granted patents cover important aspects of Hemostemix platform technology and strengthen our intellectual property portfolio, particularly in the USA and Canada, where ACP-01 is currently in a phase 2 clinical trial" said Dr. Ina Sarel, Vice President of Research and Development at Hemostemix.
These patents are part of a broad technology platform protected by a growing number of more than 40 patents issued in the United States, Canada, Europe, Japan, China and additional territories. Furthermore, Hemostemix has additional applications around all aspects of its technology pending.
ABOUT HEMOSTEMIX INC.
Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company to test a stem-cell therapy in an international, multicenter, phase 2 clinical trial for patients with critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The phase 2 trial targets a participant's diseased tissue with proprietary cells grown from his or her blood that are capable of supporting the formation of new blood vessels. The Company recently received FDA clearance to commence clinical trials in the United States.Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol HEM and on the OTCQX® Best Market under the trading symbol HMTXF.
Neither the TSX Venture Exchange Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.